Is ADPT Outperforming Medical Stocks This Year?

Overview of Adaptive Biotechnologies and the Medical Sector

Investors who are interested in the medical sector often seek out companies that show strong performance and promising growth potential. One such company is Adaptive Biotechnologies (ADPT), which has attracted attention due to its impressive returns. However, the question remains: how does ADPT's performance stack up against the broader medical sector?

Adaptive Biotechnologies is part of a larger group of 974 companies within the medical industry. This group is ranked #8 in the Zacks Sector Rank, which evaluates sectors based on the average Zacks Rank of individual companies. The Zacks Rank system focuses on earnings estimates and revisions, identifying stocks with improving earnings outlooks. This approach has historically shown success, as these stocks tend to outperform the market over the next one to three months.

Currently, Adaptive Biotechnologies holds a Zacks Rank of #2, which is categorized as "Buy." This indicates that analysts have a positive outlook for the company's future earnings. Over the past 90 days, the Zacks Consensus Estimate for ADPT’s full-year earnings has increased by 17.6%, reflecting growing confidence among analysts.

Since the start of the year, Adaptive Biotechnologies has delivered a return of approximately 116.9%. In comparison, the average return for medical companies has been -1.4%, meaning that ADPT has significantly outperformed its sector. This strong performance highlights the company's potential as an attractive investment opportunity.

Performance of Other Medical Stocks

Another notable player in the medical sector is Cardinal Health (CAH). So far this year, CAH has returned 25.2%, which is higher than the average for the sector. This makes it another stock worth considering for investors looking to diversify their portfolios within the medical industry.

Cardinal Health has also seen improvements in its earnings estimates. Over the past three months, the consensus EPS estimate for the current year has increased by 4.5%, reinforcing the positive sentiment around the company. Like ADPT, Cardinal Health currently holds a Zacks Rank of #2 (Buy), indicating strong analyst confidence.

Industry-Specific Performance

Adaptive Biotechnologies operates within the Medical - Biomedical and Genetics industry, which includes 486 stocks. This industry is ranked #102 in the Zacks Industry Rank. So far this year, stocks in this group have gained about 4.3%, while ADPT has outperformed the group with its 116.9% return.

In contrast, Cardinal Health is part of the Medical - Dental Supplies industry, which consists of 14 stocks and is ranked #172. This industry has seen a slight decline of -0.5% year-to-date, making Cardinal Health’s performance even more impressive given its 25.2% return.

Conclusion

For investors focused on the medical sector, both Adaptive Biotechnologies and Cardinal Health represent compelling opportunities. Their strong performances, supported by positive earnings outlooks and favorable Zacks Rankings, suggest that they could continue to deliver solid returns in the coming months.

As always, it is important for investors to conduct thorough research and consider their own financial goals before making any investment decisions. Keeping an eye on these two stocks could be a wise move for those looking to capitalize on the medical sector's growth potential.